NASDAQ:RNAZ

Transcode Therapeutics Stock Insider Trading

etoro logo Buy RNAZ
*Your capital is at risk
$4.56
-0.690 (-13.14%)
At Close: Jul 31, 2026

TransCode Therapeutics Stock Insider Power

Based on the 82 latest insides trades, we have calculated the insider power to be negative at 0. In total, the insiders bought 8.16M and sold 0 RNAZ shares in the last 82 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 82 transactions)
0
Buy 8.16M shares
Sell 0 shares
100% Buy Activity
Negligible or No Correlation

No Significant Signals

No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date Type Person Role Amount
Jun 22, 2022
Buy
Stock Option (Right to Buy)
A-Award
Marquet Magda
Director
Director 9 500
Value: $11.8K
Jun 22, 2022
Buy
Stock Option (Right to Buy)
A-Award
Manting Erik
Director 9 500
Value: $0
Jun 22, 2022
Buy
Stock Option (Right to Buy)
A-Award
Marquet Magda
Director 9 500
Value: $0
Jun 22, 2022
Buy
Stock Option (Right to Buy)
A-Award
Calais Philippe
Director 9 500
Value: $0
Jun 16, 2022
Buy
Common Stock
P-Purchase
Fitzgerald Thomas A
Chief Financial Officer
C-Suite Officer 12 000
Value: $15.2K
Jun 16, 2022
Buy
Common Stock
P-Purchase
Fitzgerald Thomas A
Chief Financial Officer
C-Suite Officer 12 000
Value: $15.2K
May 27, 2022
Buy
Common Stock
P-Purchase
Dudley Robert Michael
Chief Executive Officer
CEO / President 28 000
Value: $51.6K
May 27, 2022
Buy
Common Stock
P-Purchase
Dudley Robert Michael
Chief Executive Officer
CEO / President 28 000
Value: $51.6K
Mar 01, 2022
Buy
Stock Option (Right to Buy)
A-Award
Fitzgerald Thomas A
Chief Financial Officer
C-Suite Officer 52 000
Value: $0
Mar 01, 2022
Buy
Stock Option (Right to Buy)
A-Award
Fitzgerald Thomas A
Chief Financial Officer
C-Suite Officer 52 000
Value: $0
Feb 01, 2022
Buy
Stock Option (Right to Buy)
A-Award
Medarova Zdravka
Chief Technology Officer
Officer 33 000
Value: $0
Feb 01, 2022
Buy
Stock Option (Right to Buy)
A-Award
Medarova Zdravka
Chief Technology Officer
Officer 33 000
Value: $0
Feb 01, 2022
Buy
Stock Option (Right to Buy)
A-Award
Fitzgerald Thomas A
Chief Financial Officer
C-Suite Officer 33 000
Value: $80.9K
Feb 01, 2022
Buy
Stock Option (Right to Buy)
A-Award
Dudley Robert Michael
Chief Executive Officer
CEO / President 135 000
Value: $330.8K
Feb 01, 2022
Buy
Stock Option (Right to Buy)
A-Award
Fitzgerald Thomas A
Chief Financial Officer
C-Suite Officer 33 000
Value: $80.9K
Feb 01, 2022
Buy
Stock Option (Right to Buy)
A-Award
Dudley Robert Michael
Chief Executive Officer
CEO / President 135 000
Value: $330.8K
Jul 08, 2021
Buy
Stock Option (Right to Buy)
Fitzgerald Thomas A
Vp, Chief Financial Officer
C-Suite Officer 242 622
Value: $19.9K
Jul 08, 2021
Buy
Stock Option (Right to Buy)
Manting Erik
Director
Director 36 393
Value: $142.2K
Jul 08, 2021
Buy
Common Stock
Fitzgerald Thomas A
Vp, Chief Financial Officer
C-Suite Officer 0
Value: $0
Jul 08, 2021
Buy
Common Stock
Calais Philippe
Director
Director 0
Value: $0
Jul 08, 2021
Buy
Stock Option (Right to Buy)
Calais Philippe
Director
Director 36 393
Value: $142.2K
Jul 08, 2021
Buy
Stock Option (Right to Buy)
Marquet Magda
Director
Director 36 393
Value: $142.2K
Jul 08, 2021
Buy
Common Stock
Dudley Robert Michael
Chief Executive Officer
CEO / President 0
Value: $0
Jul 08, 2021
Buy
Stock Option (Right to Buy)
Dudley Robert Michael
Chief Executive Officer
CEO / President 818 852
Value: $74.5K
Jul 08, 2021
Buy
Common Stock
Fitzgerald Thomas A
Vp, Chief Financial Officer
C-Suite Officer 0
Value: $0

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT TRANSCODE THERAPEUTICS, INC.
TransCode Therapeutics
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inh...
GOLDEN STAR
Ticker Change Signal Date
FOX
$50.81
2.22% Jul 27
UNFI
$49.05
3.63% Jul 27
BIIB
$202.19
0.376% Jul 24
TSCO
$30.32
1.48% Jul 23
S
SW
$43.71
5.17% Jul 23

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE